Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Buy
58
TNXP Quote, Financials, Valuation and Earnings
Last price:
$0.39
Seasonality move
:
8.91%
Day range:
$0.40 - $0.53
52-week range:
$0.12 - $14.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.63x
P/B ratio:
1.02x
Volume:
180.5M
Avg. volume:
136.3M
1-year change:
-96.84%
Market cap:
$75.3M
Revenue:
$7.8M
EPS (TTM):
-$101.00
Analysts' Opinion
-
Consensus RatingTonix Pharmaceuticals Holding has received a consensus rating of . The company's average rating is a based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.83, Tonix Pharmaceuticals Holding has an estimated upside of 1347.12% from its current price of $0.40.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.50 representing 100% downside risk from its current price of $0.40.
Fair Value
-
According to the consensus of 0 analysts, Tonix Pharmaceuticals Holding has 1347.12% upside to fair value with a price target of $5.83 per share.
TNXP vs. S&P 500
-
Over the past 5 trading days, Tonix Pharmaceuticals Holding has underperformed the S&P 500 by -25.24% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Tonix Pharmaceuticals Holding does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Tonix Pharmaceuticals Holding has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Tonix Pharmaceuticals Holding reported revenues of $2.8M.
Earnings Growth
-
Tonix Pharmaceuticals Holding has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Tonix Pharmaceuticals Holding reported earnings per share of -$0.23.
Enterprise value:
55.1M
EV / Invested capital:
0.67x
Price / LTM sales:
0.63x
EV / EBIT:
--
EV / Revenue:
4.88x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.80x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$2.3M
Return On Assets:
-113.77%
Net Income Margin (TTM):
-1197.86%
Return On Equity:
-150.01%
Return On Invested Capital:
-139.38%
Operating Margin:
-492.06%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $11.3M | $4M | $2.8M | |
| Gross Profit | -- | $1.6M | $2.3M | $1.6M | $1.3M | |
| Operating Income | -$108.8M | -$123.8M | -$80.9M | -$28.1M | -$13.9M | |
| EBITDA | -$108.4M | -$119.9M | -$76.7M | -$26.9M | -$13.4M | |
| Diluted EPS | -$1,150.16 | -$302.58 | -$101.00 | -$38.63 | -$0.23 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $62M | $195.1M | $151.1M | $31.3M | $50.5M | |
| Total Assets | $67.6M | $214.8M | $242.6M | $139.3M | $95M | |
| Current Liabilities | $4.4M | $12M | $13.3M | $17.7M | $15.2M | |
| Total Liabilities | $5M | $12.6M | $13.7M | $18.4M | $20.8M | |
| Total Equity | $62.6M | $202.2M | $228.9M | $120.8M | $74.2M | |
| Total Debt | -- | -- | -- | -- | $8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$98.2M | -$102M | -$68.6M | -$23.4M | -$18.8M | |
| Cash From Investing | -$69.1M | -$33.3M | -$548K | -$821K | -$9K | |
| Cash From Financing | $124.4M | $3M | $90.4M | $6.3M | $42.9M | |
| Free Cash Flow | -$167.3M | -$114.1M | -$69.2M | -$25.2M | -$18.8M | |
TNXP
Sector
Market Cap
$75.3M
$45.6M
Price % of 52-Week High
2.86%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
-276.12%
-0.74%
1-Year Price Total Return
-96.84%
-31.35%
Beta (5-Year)
2.232
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.41
200-day SMA
Sell
Level
$2.41
Bollinger Bands (100)
Buy
Level
0.1 - 0.36
Chaikin Money Flow
Sell
Level
-2.2B
20-day SMA
Buy
Level
$0.28
Relative Strength Index (RSI14)
Buy
Level
57.13
ADX Line
Buy
Level
11.7
Williams %R
Neutral
Level
-78.8484
50-day SMA
Buy
Level
$0.20
MACD (12, 26)
Buy
Level
0.08
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
2.9B
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-7.4092)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
Stock Forecast FAQ
In the current month, TNXP has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TNXP average analyst price target in the past 3 months is $5.83.
-
Where Will Tonix Pharmaceuticals Holding Stock Be In 1 Year?
According to analysts, the consensus estimate is that Tonix Pharmaceuticals Holding share price will rise to $5.83 per share over the next 12 months.
-
What Do Analysts Say About Tonix Pharmaceuticals Holding?
Analysts are divided on their view about Tonix Pharmaceuticals Holding share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Tonix Pharmaceuticals Holding is a Sell and believe this share price will drop from its current level to $2.50.
-
What Is Tonix Pharmaceuticals Holding's Price Target?
The price target for Tonix Pharmaceuticals Holding over the next 1-year time period is forecast to be $5.83 according to 0 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TNXP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Tonix Pharmaceuticals Holding is a . 0 of 0 analysts rate the stock a at this time.
-
How Can I Buy Shares Of TNXP?
You can purchase shares of Tonix Pharmaceuticals Holding via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Tonix Pharmaceuticals Holding shares.
-
What Is The Tonix Pharmaceuticals Holding Share Price Today?
Tonix Pharmaceuticals Holding was last trading at $0.39 per share. This represents the most recent stock quote for Tonix Pharmaceuticals Holding. Yesterday, Tonix Pharmaceuticals Holding closed at $0.40 per share.
-
How To Buy Tonix Pharmaceuticals Holding Stock Online?
In order to purchase Tonix Pharmaceuticals Holding stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 7.34% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 0.76% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is down 0.68% over the past day.
